<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734497</url>
  </required_header>
  <id_info>
    <org_study_id>Spinal anesthesia-FTc</org_study_id>
    <nct_id>NCT03734497</nct_id>
  </id_info>
  <brief_title>Carotid Flow Time Measurement Guided Fluid Management During Spinal Anesthesia</brief_title>
  <official_title>Carotid Flow Time Measurement Guided Fluid Management During Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Teaching and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Teaching and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fluid management is a fundamental aspect of anesthesia. Several monitorization methods have
      been introduced to optimize fuid management.

      To date neither of them were ideal. Corrected flow time measurement (FTc) in the carotid
      artery was recently introduced to detect fluid responsiveness.

      Spinal anesthesia causes hypotension and fluid preloading is suggested to overcome this
      problem.

      The aim of this study is to evaluate the effect of FTc guided fluid loading on spinal
      anesthesia induced hypotension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be randomly allocated into 3 groups. Group C (Control) will receive spinal
      anesthesia after initiation of intravenous (iv) access without fluid preloading and will
      receive 2 ml/kg Ringer's lactate during anesthesia..

      Group P (preloading) will receive 10 ml/kg Ringer's lactate before spinal block.

      In Group FTc, ultrasonographic measurement of corrected flow time in carotid artery will be
      measured using 10-5 megahertz linear probe. On the two-dimensional image, the optimal image
      of the long-axis view will be obtained at the left common carotid artery. The sample volume
      will be placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave
      Doppler examination will be performed. Cardiac cycle time and carotid flow time will be
      measured. Carotid flow time will be measured between the upstroke of the flow tracing and the
      dicrotic notch, and it will be corrected for pulse rate by dividing flow time by the square
      root of the cardiac cycle time to calculate corrected carotid artery flow time (flow
      time/√cycle time).

      The blood pressure will be measured 5 minutes before spinal anesthesia is commenced
      (baseline) and every minute afterwards until end of surgery.

      Group FTc will receive a 500 mL Ringer's lactate bolus if the FTc is &lt;349 ms (fluid
      responder); the FTc measurement will be repeated 15 minutes later and additional 500 mL
      Ringer's lactate bolus will be applied if the patient is still considered fluid responder;
      this sequence will be repeated until the patient's FTc is &gt; 349 ms (non responder).

      Ephedrine bolus will be used in allh groups if the mean arterial pressure drops below 30% of
      the baseline value.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomised</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with Hypotension</measure>
    <time_frame>5 minutes after induction of spinal anesthesia</time_frame>
    <description>Mean arterial pressure &gt;30% lower than baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients receiving Vasopressor therapy</measure>
    <time_frame>5 minutes after induction of spinal anesthesia</time_frame>
    <description>Ephedrine will be administered if mean arterial pressure drops &gt;30% than baseline value</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Meniscus Disorder</condition>
  <arm_group>
    <arm_group_label>Group Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive 2 ml/kg &quot;Ringer's lactate&quot; Lafleks® during anesthesia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Preloading</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 10 ml/kg &quot;Ringer's lactate&quot; Lafleks® fluid preloading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Carotis FTc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>will receive 500 ml &quot;Ringer's lactate&quot; Lafleks® if the patient is fluid responder</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Carotis FTc 500 ml &quot;Ringer's lactate&quot; Lafleks®</intervention_name>
    <description>will receive 500 ml &quot;Ringer's lactate&quot; Lafleks® if the patient is fluid responder</description>
    <arm_group_label>Group Carotis FTc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Preloading 10 ml/kg &quot;Ringer's lactate&quot; Lafleks®</intervention_name>
    <description>will receive 10 ml/kg &quot;Ringer's lactate&quot; Lafleks® fluid preloading</description>
    <arm_group_label>Group Preloading</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Control 2 ml/kg &quot;Ringer's lactate&quot; Lafleks®</intervention_name>
    <description>will receive 2 ml/kg &quot;Ringer's lactate&quot; Lafleks® during anesthesia</description>
    <arm_group_label>Group Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (19-80 years of age) who were scheduled to undergo arthroscopic knee
             surgery under spinal anesthesia

        Exclusion Criteria:

          -  Mean blood pressure &lt; 70 mmHg before induction of general anesthesia

          -  Patients who have currently taken angiotensin-converting enzyme inhibitor

          -  Patients who have currently taken angiotensin receptor blocker

          -  the presence of carotid artery stenosis &gt; 50%

          -  cardiac rhythm other than sinus

          -  unstable angina

          -  a left ventricular ejection fraction of &lt; 40%

          -  severe vascular disease

          -  implanted pacemaker/cardioverter

          -  autonomic nervous system disorders

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dilek Ünal</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Health Sciences Dıskapı Yıldırım Beyazıt Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dilek Ünal, Assoc.Prof.</last_name>
    <phone>05336957855</phone>
    <email>dilek.yazicioglu@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diskapi Yildirim Beyazit Teaching and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06110</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Lee JE, George RB, Habib AS. Spinal-induced hypotension: Incidence, mechanisms, prophylaxis, and management: Summarizing 20 years of research. Best Pract Res Clin Anaesthesiol. 2017 Mar;31(1):57-68. doi: 10.1016/j.bpa.2017.01.001. Epub 2017 Jan 8. Review.</citation>
    <PMID>28625306</PMID>
  </reference>
  <results_reference>
    <citation>Song Y, Kwak YL, Song JW, Kim YJ, Shim JK. Respirophasic carotid artery peak velocity variation as a predictor of fluid responsiveness in mechanically ventilated patients with coronary artery disease. Br J Anaesth. 2014 Jul;113(1):61-6. doi: 10.1093/bja/aeu057. Epub 2014 Apr 9.</citation>
    <PMID>24722322</PMID>
  </results_reference>
  <results_reference>
    <citation>Ceruti S, Anselmi L, Minotti B, Franceschini D, Aguirre J, Borgeat A, Saporito A. Prevention of arterial hypotension after spinal anaesthesia using vena cava ultrasound to guide fluid management. Br J Anaesth. 2018 Jan;120(1):101-108. doi: 10.1016/j.bja.2017.08.001. Epub 2017 Nov 23.</citation>
    <PMID>29397116</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 1, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Teaching and Research Hospital</investigator_affiliation>
    <investigator_full_name>DILEK YAZICIOGLU</investigator_full_name>
    <investigator_title>Assoc Prof</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

